The National Authority for Medicines and Health Products (Infarmed) is evaluating whether the state will pay for a new brain cancer drug called Voranigo. The evaluation follows a rejected special authorization request for a 35-year-old patient, though the agency is now considering a more general approval for use in public hospitals. Patients and families should note that the drug targets specific gliomas and has already been approved for use in other jurisdictions.